Agoracom Blog Home

Posts Tagged ‘Kai Medical Laboratory’

VIDEO – Empower Clinics $CBDT.ca $EPWCF In Advanced Discussions With Large US Pharmacies As Proposed Acquisition Includes Products In 4,000 Canadian Pharmacies $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 5:57 PM on Thursday, June 3rd, 2021

As if today’s press release wasn’t good enough Empower Clinics Announces Major Expansion with Proposed Acquisition of Medisure Canada. Diabetes Tests and Devices Carried In 4,000 Pharmacies and Generated $1.9m in 2020 Revenue, shareholders also received this injection of confidence from CEO

Steve McAuley:

“As I’ve stated to our shareholders on multiple occasions throughout 2021, Empower is in the strongest position it has ever been and will continue to grow every aspect of our business unabated and without interruption. In addition to this acquisition, in the last 30 days alone we have announced expansions of our clinics, gone live on our KAI Saliva RT-PCR test with Air Canada and are very advanced on tripling the size of the KAI Medical Laboratory facility. We are hitting on all cylinders and well on our way to becoming a major vertically integrated healthcare company. I fully expect Empower to have continued strong business announcements in June and throughout 2021″

If that was all, it would be a great day … and it was with $CBDT closing up 16.5% on 7.5M shares to $0.53 … but then Steve shared some powerful information about leveraging this acquisition with large US pharmacies.  

Who did he name? 

Watch this great interview with CEO Steve McAuley.

VIDEO – Watch Our Latest Shareholder Q&A With @EmpowerClinics $CBDT $EPWCF

Posted by AGORACOM-JC at 9:06 PM on Thursday, April 15th, 2021

Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Surpasses 1,000 COVID-19 Tests in A Day for The First Time Ever. KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1 $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:47 AM on Tuesday, February 16th, 2021

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and travel industry

  • Announced KAI Medical Laboratory (“KAI LAB”) has exceeded 1,000 COVID-19 test units in a single day for the first time.
  • As a result, Empower is announcing that KAI LAB will undergo an even larger expansion in anticipation of projected growth in COVID-19 test requirements in the U.S., Canada and international markets.

VANCOUVER BC / February 16, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce our KAI Medical Laboratory (“KAI LAB”) has exceeded 1,000 COVID-19 test units in a single day for the first time.

As a result, Empower is announcing that KAI LAB will undergo an even larger expansion in anticipation of projected growth in COVID-19 test requirements in the U.S., Canada and international markets.

KAI MEDICAL LABORATORY NOW EXPANDING TO TRIPLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED RAPID TEST GROWTH

KAI Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI experienced significant growth in its first quarter under Empower (October 2020 – December 2020), with Q4 COVID-19 test units exceeding 6,000 specimens processed, far surpassing the less than 1,000 total monthly units prior to acquisition.

As a result, on January 21st, Empower announced “Doubling KAI Medical Laboratory In Anticipation Of Test Volumes By End Of Q1.” The Company is revising this planned expansion upwards by announcing KAL LAB is now expanding by tripling its current size in anticipation of projected growth in COVID-19 test requirements.

Empower Clinics Chairman & CEO, Steven McAuley stated “Today marks a significant milestone for Empower and our shareholders. When we first acquired KAI Medical Laboratory just over four months ago, it was processing less than 1,000 specimens monthly up to that point. Today, we are announcing that KAI has surpassed 1,000 units in a day for the first time ever. This is a credit to both Yoshi Tyler, President KAI LAB and her fantastic team, supported by our business development and marketing strategies which, quite frankly, are still in an early phase. We are just getting started.”

For the purposes of facilitating the expansion, Empower has secured additional space adjacent to KAI LAB in order to separate the lab & science from logistics, admin and customer support. Materials handling staff are being added in anticipation of processing the intake of thousands of packages per day.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/755396-empower-clinics-kai-medical-laboratory-surpasses-1-000-covid-19-tests-in-a-day-for-the-first-time-ever-kai-laboratory-now-tripling-in-size/messages/2303796#message

Empower Clinics $CBDT.ca $EPWCF Secures Medical Device Establishment Licence (MDEL) Status To Sell KAI Saliva COVID-19 PCR Test Kits In Canada $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:05 AM on Wednesday, February 10th, 2021
  • Announced it has secured Medical Device Establishment Licence (“MDEL”) status to sell its KAI Medical COVID-19 Saliva Test kits (“KAI Saliva”).
  • KAI Saliva is FDA EUA approved for use, has CE Mark and the saliva specimen collection device is approved by Health Canada.
  • KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into to Canada or arriving to other countries that have similar executive travel orders.

VANCOUVER BC / February 10, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce it has secured Medical Device Establishment Licence (“MDEL”) status to sell its KAI Medical COVID-19 Saliva Test kits (“KAI Saliva”).

KAI Saliva is FDA EUA approved for use, has CE Mark and the saliva specimen collection device is approved by Health Canada. KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into to Canada or arriving to other countries that have similar executive travel orders.

EMPOWER ACCELERATES ABILITY TO DISTRIBUTE AND SELL MEDICAL DEVICE PRODUCTS IN CANADA THROUGH PARTNERSHIP WITH MEDIPRO CANADA

Empower previously announced the filing of an MDEL application for the purpose of importing, distributing and selling KAI Saliva, which has experienced success upon its launch.

To accelerate the process, Empower partnered with MediPro Canada Inc. (“MediPro”) to utilize their approved MDEL status. MediPro provides healthcare products for governments, large corporations and medical facilities around the world and is led by Hon. Sheila Maureen Copps PC OC.

“We continue to see extensive demand for novel COVID-19 testing products in both private sector and public sector markets throughout North America, Mexico and Caribbean countries.” said Hon. Sheila Copps OC, Partner MediPro Canada. “Leveraging the vast network of MediPro Canada with the integrated healthcare capabilities of Empower Clinics and their novel COVID-19 testing products, makes for an ideal partnership.”

“We all have an urgent requirement for a home-based, self-administered COVID-19 saliva test kit that can help open up the economy and facilitate travel that meets the requirements of the executive travel orders.” said Steven McAuley, Chairman & CEO. “We also must utilize our resources, our reach, our capability, do everything we can to assist, be humanitarians, use our voice, strive to provide improved healthcare, and lead the path of progressive healthcare.”

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/755072-empower-clinics-secures-medical-device-establishment-licence-mdel-status-to-sell-kai-saliva-covid-19-pcr-test-kits-in-canada/messages/2303015#message

Empower $CBDT.ca $EPWCF Partners with #Rexall $MCK To Launch Integrated Healthcare Centres $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 12:26 PM on Tuesday, February 9th, 2021

Partnership Accelerates Empower’s Strategy To Execute National Healthcare Centre Expansion By Bringing Accessible and Progressive Primary Care and Para-Medical Care to Millions of Canadians

  • Announced effective February 8, 2021 a partnership with Rexall Pharmacy Group to launch the first of multiple integrated healthcare centres within Rexall pharmacies commencing in Ontario, Canada.
  • Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location.

VANCOUVER, BC / February 9, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce effective February 8, 2021 a partnership with Rexall Pharmacy Group to launch the first of multiple integrated healthcare centres within Rexall pharmacies commencing in Ontario, Canada.

“In our first press release of 2021 announcing the closing of our Canadian Clinics acquisition, I stated Empower had a winning business model with immediate expansion plans throughout Greater Toronto, followed by Ontario and then nationwide with at least 30 clinics in rapid succession. Empower is proud to begin delivering on that promise.” said Steven McAuley, Chairman & CEO. “To say this is the Company’s biggest announcement in its history would not be an over statement. This partnership with Rexall accelerates our nationwide healthcare expansion strategy, I look forward to bringing Six Sigma philosophies and continuous process improvements to our operations to ensure customers and our patients have access to our primary care and para-medical services for years to come. Today marks a major win for Canadian healthcare and the shareholders of Empower Clinics.”

PARTNERSHIP IDENTIFIES INITIAL LOCATIONS IN ONTARIO

Rexall and Empower have identified numerous initial locations throughout Ontario, spanning from Ottawa to London and around the GTA. The size of the locations can range from 1,500 to 4,000 square feet. As each new location is agreed upon, key terms are outlined in a letter of intent and in the lease or sub-lease agreements with the first anticipated agreements February 2021.

HEALTH CARE SERVICES TO BE DELIVERED

Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location.

Primary care services include:

  • Family physicians
  • Walk-in physicians
  • Tele-medicine and virtual care

Paramedical services include:

  • Chiropractic
  • Physiotherapy
  • Registered Massage Therapy
  • Chiropody
  • Acupuncturists
  • Osteopaths
  • Nutritionists

ADDITIONAL HEALTH CARE SERVICES EXPECTED TO BE ADDED

Given the anticipated expansion and penetration of Empower Clinics into the Canadian market, the Company intends to continue adding valuable specialized medical services to strengthen the quality of healthcare at each location that can include:

  • Dermatology
  • Cardiology

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/754999-empower-partners-with-rexall-r-to-launch-integrated-healthcare-centres/messages/2302856#message

Empower Clinics $CBDT.ca $EPWCF Subsidiary KAI Medical Laboratory Awarded #COVID-19 Testing & Healthcare Management Program for Five Million Square Foot Dallas Market Center, The Most Complete Wholesale Trade Resource in The World With $8 Billion USD In Annual Transactions $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:05 AM on Monday, February 1st, 2021

  • Awarded a long-term COVID-19 testing and healthcare management program for the Dallas Market Center, the leading wholesale marketplace in North America and the most complete wholesale trade resource in the world.
  • DMC is a five million square foot, global business-to-business trade center and the leading wholesale marketplace in North America connecting retailers and interior designers with top manufacturers in home décor, furniture, gifts, lighting and fashion.

VANCOUVER BC / February 1, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (EPWCF:OTCQB) (8EC:Frankfurt) (“Empower” or the “Company“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens each month, developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce that KAI Medical Laboratory has been awarded a long-term COVID-19 testing and healthcare management program for the Dallas Market Center (“DMC”), the leading wholesale marketplace in North America and the most complete wholesale trade resource in the world.

KAI TO PROVIDE DAILY ONSITE COVID TESTING TO KEEP FIVE MILLION SQUARE FOOT TRADE CENTER OPEN TO BUYERS AND SELLERS FROM AROUND THE WORLD

DMC is a five million square foot, global business-to-business trade center and the leading wholesale marketplace in North America connecting retailers and interior designers with top manufacturers in home décor, furniture, gifts, lighting and fashion. DMC markets events throughout the year attracting buyers and sellers from all 50 states and more than 80 countries, resulting in significant economic impact:

  • $8 Billion in annual wholesale transactions
  • $1.1 Billion in indirect local economic impact
  • $380 million in direct local economic impact

“We cannot recover from crises like the COVID-19 pandemic without a resilient retail sector and the market centers have a critical role in participating in that recovery,” said Harlan Crow, chairman of the company that owns DMC in a January 3, 2021 Forbes Article.

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/754316-empower-clinics-subsidiary-kai-medical-laboratory-awarded-covid-19-testing-healthcare-management-program-for-five-million-square-foot/messages/2301340#message

VIDEO – Empower Clinics $CBDT.ca $EPWCF CEO Answers Shareholder Questions In First Ever Shareholder Q&A $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 9:20 PM on Thursday, January 21st, 2021

On behalf of Steve and the Empower Clinics team, we are happy to present the first ever Empower Clinics Shareholder Q&A.  

Thanks to all investors that posted their questions here on AGORACOM and on Twitter.

Enjoy this video with Steve from an undisclosed location that he reveals during the interview.

Empower Clinics $CBDT.ca $EPWCF Doubling KAI Medical Laboratory Size In Anticipation Of Test Volumes By End Of Q1. Files MDEL Application With Health Canada To Import and Sell KAI Saliva PCR Test In Canada $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:58 AM on Thursday, January 21st, 2021

  • Announced significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.
  • In addition, Empower has filed a Medical Device Establishment Licence with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test, which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.

VANCOUVER, BC / January 21, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.

In addition, Empower has filed a Medical Device Establishment Licence (“MDEL”) with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test (“KAI Saliva”), which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.

KAI MEDICAL LABORATORY EXPANDING TO AT LEAST DOUBLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED GROWTH IN VOLUME

KAI Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI experienced significant growth in its first quarter under Empower, with Q4 COVID-19 test kit volumes exceeding 6,000 units, far surpassing the 1,300 total units prior to acquisition.

Current run rate projections now indicate as follows:

  • January 2021 is expected to exceed 8,000 tests, surpassing all of Q4 2020
  • February 2021 could see daily rates hit 1,000 tests per day
  • March 2021 could see daily rates hit 2,000 tests per day

These run rates DO NOT include the recent 25,000 unit order for KAI Saliva test kits, nor do they include any test kits from the launch of KAItests.com

Empower Clinics CEO, Steven McAuley stated “Our investment in R&D is really starting to pay off for KAI Medical, starting with a new state-of-art laboratory information system to automate processes for the anticipated growth in volume. Next, we have hired three new scientists, increased administrative staff and are activating a call center to provide world-class customer support. Further, the investment in new test protocols such as the Kai Saliva test kit, combined with our Health Canada medical device licence, positions us to be a leader in the reactivation of travel for Canadians.”

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/753555-empower-clinics-doubling-kai-medical-laboratory-size-in-anticipation-of-test-volumes-by-end-of-q1-files-mdel-application-with-health-canada-to/messages/2299214#message

Empower Clinics $CBDT.ca $EPWCF Announces First Ever AGORACOM Video Q&A with Shareholders Submitting Questions for Direct Response by CEO Steven McAuley $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:47 AM on Tuesday, January 19th, 2021

Shareholders are able to submit questions by either:

  • Posting directly to the Empower Verified Forum on AGORACOM at https://agoracom.com/ir/EmpowerClinics/forums/discussion and checking the “?” box
  • Posting on Twitter to both @EmpowerClinics and @Agoracom with the any of the following hashtags #empowerclinics_QA, #CBDTQA, #CBDT_QA

Questions must be posted by no later than Wednesday, January 20th, 5PM EST.

With Empower Clinics Entering Growth Phase On Multiple Business Fronts, Chairman & CEO Steven McAuley Provides Shareholders With An Opportunity To Fully Participate In Company’s First AGORACOM Video Q&A

VANCOUVER, BC / January 19, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical clinics in USA and Canada, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce its first ever AGORACOM Video Q&A, which provides investors with the opportunity to submit questions for response by Chairman & CEO Steven McAuley.

Empower Clinics CEO Steven McAuley stated “With so much tremendous progress taking place for our company, as we head into what I expect to be our breakthrough and greatest year ever in 2021, I want to make sure shareholders have an opportunity to ask questions, receive answers directly from me and begin the process of regular engagement through our Verified Forum on AGORACOM. I am looking forward to engaging with shareholders and followers on the interview.”

VIDEO Q&A DETAILS

Shareholders are able to submit questions by either:

  • Posting directly to the Empower Verified Forum on AGORACOM at https://agoracom.com/ir/EmpowerClinics/forums/discussion and checking the “?” box
  • Posting on Twitter to both @EmpowerClinics and @Agoracom with the any of the following hashtags #empowerclinics_QA, #CBDTQA, #CBDT_QA

Questions must be posted by no later than Wednesday, January 20th, 5PM EST.

Read more: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/753351-empower-clinics-announces-first-ever-agoracom-video-q-a-with-shareholders-submitting-questions-for-direct-response-by-ceo-steven-mcauley/messages/2298759#message

Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Sells Out First 5,000 Units Of FDA EUA Approved Saliva #COVID-19 Test Kits. Issues Order For Next 25,000 KAI Saliva PCR Test Kits With Sales Value Of $5.5M. Discussions With Major Airlines Underway $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:44 AM on Thursday, January 7th, 2021

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas,TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and colleges

  • Announced the successful launch of our KAI Saliva PCR Test with our initial soft launch of 5,000 units sold out and the order of 25,000 additional units with a sales value of approximately $5,500,000.
  • Initial and overwhelming demand for KAI Saliva stemmed from our existing customers in film & television productions, the commercial sector, and concierge testing supported by Sun Valley Health in Arizona.
  • Given the early and significant success of KAI Saliva since its launch on December 15, 2020, Empower is extremely confident in the continued success of KAI Saliva with both existing and expanded commercial customers in this next run.

VANCOUVER, BC / January 7, 2021 / EMPOWER CLINICS INC. (CBDT:CSE)(8EC:Frankfurt)(EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce the successful launch of our KAI Saliva PCR Test (“KAI Saliva”) with our initial soft launch of 5,000 units sold out and the order of 25,000 additional units with a sales value of approximately $5,500,000.

INITIAL DEMAND FOR FIRST RUN KAI SALIVA CAME FROM EXISTING COMMERCIAL CUSTOMERS, INCLUDING FILM & TELEVISION PRODUCTIONS. DIRECT TO CONSUMER CHANNEL LAUNCH IMMINENT

Initial and overwhelming demand for KAI Saliva stemmed from our existing customers in film & television productions, the commercial sector, and concierge testing supported by Sun Valley Health in Arizona. Given the early and significant success of KAI Saliva since its launch on December 15, 2020, Empower is extremely confident in the continued success of KAI Saliva with both existing and expanded commercial customers in this next run.

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/752516-empower-clinics-kai-medical-laboratory-sells-out-first-5-000-units-of-fda-eua-approved-saliva-covid-19-test-kits/messages/2296434#message